Thomas Gajewski

Dr. Thomas Gajewski is a scientific advisor to FogPharma and currently serves as a professor in, departments of pathology and medicine, a section of hematology/oncology at the University of Chicago. There, he is the leader of the immunology and cancer program of the Cancer Center and also directs the Melanoma Oncology Clinic. Dr. Gajewski is past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Discovery, Journal for ImmunoTherapy of Cancer, and Journal of Experimental Medicine. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn, applies this information to preclinical and clinical efforts to promote anti-tumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new cancer immunotherapies for melanoma and other tumor types, using new laboratory data on how the immune system is regulated combined with genomic/bioinformatic approaches from patient samples. He has served on the program committees for the American Society for Clinical Oncology and the American Association for Cancer Research.